Marksans Pharma Ltd
NSE :MARKSANS BSE :524404 Sector : PharmaceuticalsBuy, Sell or Hold MARKSANS? Ask The Analyst
BSE
prev close
OPEN PRICE
volume
Today's low / high
52 WK low / high
bid price (qty)
offer price (qty)
NSE
prev close
open price
volume
Today's' low / high
52 WK low / high
bid price (qty)
offer price (qty)
15 Jan 262.10 (1.63%) | 14 Jan 257.90 (3.80%) | 13 Jan 248.45 (-4.63%) | 10 Jan 260.50 (-5.26%) | 09 Jan 274.95 (-2.86%) | 08 Jan 283.05 (-2.21%) | 07 Jan 289.45 (1.35%) | 06 Jan 285.60 (-4.13%) | 03 Jan 297.90 (-0.17%) | 02 Jan 298.40 (-2.05%) | 01 Jan 304.65 (2.70%) | 31 Dec 296.65 (3.08%) | 30 Dec 287.80 (-2.01%) | 27 Dec 293.70 (1.21%) | 26 Dec 290.20 (-1.19%) | 24 Dec 293.70 (-0.02%) | 23 Dec 293.75 (-3.66%) | 20 Dec 304.90 (-3.65%) | 19 Dec 316.45 (-1.12%) | 18 Dec 320.05 (-1.80%) | 17 Dec 325.90 (4.35%) |
Price Chart Historical Data Technical Chart
Technical Analysis
Short Term Investors
Bearish
Medium Term Investors
Very Bearish
Long Term Investors
Bullish
Moving Averages
5 DMA
Bullish
260.6
10 DMA
Bearish
275.68
20 DMA
Bearish
287.88
50 DMA
Bearish
306.34
100 DMA
Bearish
291.6
200 DMA
Bullish
232.78
Intraday Support and Resistance
(Based on Pivot Points) |
Updated On Jan 15, 2025 04:00 PM For Next Trading Session
Pivots | Classic | Fibonacci | Camarilla | Woodie | DM |
---|---|---|---|---|---|
R3 | 278.06 | 273.23 | 264.96 | - | - |
R2 | 273.23 | 269.26 | 264.01 | 273.05 | - |
R1 | 267.66 | 266.8 | 263.05 | 267.3 | 270.45 |
P | 262.83 | 262.83 | 262.83 | 262.65 | 264.23 |
S1 | 257.26 | 258.86 | 261.15 | 256.9 | 260.05 |
S2 | 252.43 | 256.4 | 260.19 | 252.25 | - |
S3 | 246.86 | 252.43 | 259.24 | - | - |
Key Metrics
EPS
3.39
P/E
77.27
P/B
9.2
Dividend Yield
0.23%
Market Cap
11,877 Cr.
Face Value
1
Book Value
28.49
ROE
16.53%
EBITDA Growth
145.74 Cr.
Debt/Equity
0.1
Shareholding History
Quarterly Result (Figures in Rs. Crores)
Marksans Pharma Ltd Quaterly Results
Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | ||
INCOME | 550.23 | 590.93 | 576.54 | 605.57 | 652.98 | |
PROFIT | 83.52 | 83.24 | 78.29 | 88.75 | 96.72 | |
EPS | 1.84 | 1.84 | 1.73 | 1.96 | 2.13 |
Marksans Pharma Ltd Quaterly Results
Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | ||
INCOME | 220.6 | 242.69 | 237.39 | 262.68 | 339.98 | |
PROFIT | 31.29 | 25.29 | 32.99 | 32.02 | 63.2 | |
EPS | 0.69 | 0.56 | 0.73 | 0.71 | 1.39 |
Profit & Loss (Figures in Rs. Crores)
Marksans Pharma Ltd Profit & Loss
Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | ||
INCOME | 801.33 | 897.36 | 822.12 | 900.61 | 1024.59 | 1081.59 | 1519.15 | 1519.79 | 1917.84 | 2301.69 | |
PROFIT | 109.46 | 78.5 | 8.83 | 32.98 | 76.46 | 120.73 | 235.92 | 184.57 | 266.52 | 313.59 | |
EPS | 2.71 | 1.99 | 0 | 0.87 | 1.97 | 2.95 | 5.83 | 4.56 | 5.85 | 6.95 |
Marksans Pharma Ltd Profit & Loss
Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | ||
INCOME | 407.32 | 362.66 | 222.12 | 305.81 | 434.8 | 439.22 | 630.16 | 696.65 | 725.87 | 922.59 | |
PROFIT | 67.11 | 71.48 | 11.53 | 12.43 | 43.65 | 37.87 | 98.35 | 103.99 | 102.92 | 133.69 | |
EPS | 1.61 | 1.72 | 0.19 | 0.3 | 1.07 | 0.93 | 2.4 | 2.54 | 2.27 | 2.95 |
Balance Sheet (Figures in Rs. Crores)
Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | |
SOURCES OF FUNDS : | ||||||||||
Share Capital | 45.32 | 45.32 | 40.93 | 40.93 | 40.93 | 40.93 | 40.93 | 40.93 | 53.43 | 53.43 |
Reserves Total | 2,019.74 | 1,699.85 | 1,068.24 | 845.56 | 595.08 | 501.55 | 429.93 | 392.5 | 400.89 | 326.33 |
Equity Share Warrants | 0 | 0 | 93.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Shareholders Funds | 2,065.06 | 1,745.17 | 1,202.27 | 886.49 | 636.01 | 542.48 | 470.86 | 433.43 | 454.32 | 379.76 |
Minority Interest | 20.85 | 19.91 | 20.7 | 18.86 | 13.11 | 10.22 | 9.55 | 6.25 | 8.36 | 8.1 |
Secured Loans | 29.09 | 41.59 | 41.29 | 18.74 | 18.89 | 100.22 | 117.96 | 109.71 | 87.9 | 88.59 |
Unsecured Loans | 214.97 | 81.36 | 69.49 | 15.36 | 10.76 | 0 | 0 | 0 | 0 | 0 |
Total Debt | 244.06 | 122.95 | 110.78 | 34.1 | 29.65 | 100.22 | 117.96 | 109.71 | 87.9 | 88.59 |
Other Liabilities | 4.56 | 3.25 | 1.86 | 7.11 | 6.47 | 11.36 | 11.08 | 11.96 | 0 | 0 |
Total Liabilities | 2,334.53 | 1,891.28 | 1,335.61 | 946.56 | 685.24 | 664.28 | 609.45 | 561.35 | 550.58 | 476.45 |
APPLICATION OF FUNDS : | ||||||||||
Gross Block | 1,193.49 | 828.26 | 726.27 | 551.93 | 563.24 | 506.26 | 495.35 | 456.49 | 429.47 | 297.78 |
Less: Accumulated Depreciation | 417.55 | 341.95 | 297.96 | 242.56 | 260.52 | 236.54 | 215.97 | 189.52 | 159.82 | 131.89 |
Net Block | 775.94 | 486.31 | 428.31 | 309.37 | 302.72 | 269.72 | 279.38 | 266.97 | 269.65 | 165.89 |
Capital Work in Progress | 9.42 | 9.87 | 2.57 | 11.68 | 0 | 0 | 0 | 0.36 | 0 | 0 |
Investments | 26.99 | 0.54 | 0.44 | 0.26 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 617.94 | 484.74 | 424.44 | 404.32 | 241.84 | 293.25 | 218.12 | 190.09 | 167.79 | 130.11 |
Sundry Debtors | 453.18 | 416.85 | 394.78 | 271.95 | 243.35 | 176.6 | 176.91 | 247.58 | 217.29 | 183.45 |
Cash and Bank Balance | 673.58 | 714.96 | 349.27 | 212.18 | 93.73 | 33.54 | 39.88 | 25.16 | 35.3 | 185.27 |
Loans and Advances | 90.8 | 58.22 | 32.28 | 14.11 | 14.66 | 28.06 | 15.63 | 21.06 | 19.76 | 10 |
Total Current Assets | 1,835.5 | 1,674.77 | 1,200.77 | 902.56 | 593.59 | 531.44 | 450.54 | 483.89 | 440.15 | 508.83 |
Current Liabilities | 313.94 | 257.13 | 268.82 | 242.32 | 165.9 | 126.66 | 87.35 | 162.5 | 119.66 | 140.5 |
Provisions | 21.86 | 26.6 | 18.05 | 31.88 | 40.72 | 5.74 | 29.36 | 23.85 | 51.88 | 57.15 |
Total Current Liabilities & Provisions | 335.81 | 283.73 | 286.87 | 274.19 | 206.62 | 132.41 | 116.72 | 186.35 | 171.54 | 197.65 |
Net Current Assets | 1,499.69 | 1,391.03 | 913.9 | 628.36 | 386.96 | 399.03 | 333.82 | 297.54 | 268.61 | 311.18 |
Deferred Tax Assets | 18.77 | 11.82 | 9.16 | 2.09 | 3.2 | 2.78 | 3.01 | 2.64 | 4.76 | 1.52 |
Deferred Tax Liability | 29.39 | 27.21 | 22.93 | 9.35 | 13.36 | 8.56 | 7.57 | 6.75 | 2.85 | 2.97 |
Net Deferred Tax | -10.62 | -15.39 | -13.77 | -7.26 | -10.16 | -5.78 | -4.56 | -4.11 | 1.91 | -1.45 |
Other Assets | 33.11 | 18.91 | 4.16 | 4.16 | 5.73 | 1.29 | 0.82 | 0.59 | 10.41 | 0.83 |
Total Assets | 2,334.52 | 1,891.27 | 1,335.61 | 946.56 | 685.25 | 664.27 | 609.46 | 561.36 | 550.58 | 476.46 |
Contingent Liabilities | 0 | 1.45 | 1.45 | 19.78 | 48.17 | 30.4 | 10.47 | 0 | 0 | 0 |
Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | |
SOURCES OF FUNDS : | ||||||||||
Share Capital | 45.32 | 45.32 | 40.93 | 40.93 | 40.93 | 40.93 | 40.93 | 40.93 | 53.43 | 53.43 |
Reserves Total | 1,177.39 | 1,066.01 | 650.64 | 558.79 | 464.69 | 429.64 | 388.04 | 377.95 | 369.27 | 304.75 |
Equity Share Warrants | 0 | 0 | 93.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Shareholders Funds | 1,222.71 | 1,111.33 | 784.67 | 599.72 | 505.62 | 470.57 | 428.97 | 418.88 | 422.7 | 358.18 |
Secured Loans | 0 | 0 | 0 | 0 | 0.05 | 77.63 | 66.86 | 73.23 | 40.62 | 49.93 |
Unsecured Loans | 8.13 | 7.69 | 14.31 | 14.37 | 10.76 | 0 | 0 | 0 | 0 | 0 |
Total Debt | 8.13 | 7.69 | 14.31 | 14.37 | 10.81 | 77.63 | 66.86 | 73.23 | 40.62 | 49.93 |
Other Liabilities | 4.47 | 3.18 | 1.86 | 7.11 | 6.47 | 11.36 | 11.08 | 11.96 | 0 | 0 |
Total Liabilities | 1,235.31 | 1,122.2 | 800.84 | 621.2 | 522.9 | 559.56 | 506.91 | 504.07 | 463.32 | 408.11 |
APPLICATION OF FUNDS : | ||||||||||
Gross Block | 472.78 | 318.89 | 301.34 | 277.25 | 246.62 | 224.9 | 201.83 | 195.61 | 184.48 | 162.47 |
Less : Accumulated Depreciation | 201.2 | 174.95 | 165.83 | 148.17 | 131.44 | 122.28 | 113.94 | 101.69 | 87.01 | 72.45 |
Net Block | 271.58 | 143.94 | 135.51 | 129.08 | 115.18 | 102.62 | 87.89 | 93.92 | 97.47 | 90.02 |
Capital Work in Progress | 0 | 3.91 | 0 | 0 | 0 | 0 | 0 | 0.36 | 0 | 0 |
Investments | 292.75 | 266.29 | 236.51 | 236.34 | 236.07 | 236.07 | 236.07 | 234.29 | 231.44 | 67.62 |
Inventories | 190.85 | 130.95 | 103.68 | 93.69 | 74.6 | 70.36 | 42.29 | 29.24 | 43.74 | 51.03 |
Sundry Debtors | 370.17 | 305.49 | 246.78 | 168.93 | 161.87 | 177.83 | 168.87 | 154.8 | 133.41 | 124.63 |
Cash and Bank Balance | 312.23 | 440.26 | 224.05 | 105.61 | 3.35 | 1.8 | 0.71 | 2.56 | 3.13 | 167.54 |
Loans and Advances | 47.46 | 36.52 | 14.92 | 2.89 | 4.23 | 22.01 | 20.63 | 30.01 | 23.76 | 25.46 |
Total Current Assets | 920.71 | 913.22 | 589.43 | 371.12 | 244.05 | 272.01 | 232.51 | 216.61 | 204.04 | 368.66 |
Current Liabilities | 264.45 | 206.71 | 147.64 | 100.82 | 64.29 | 44.25 | 41.92 | 21.31 | 32.08 | 78.06 |
Provisions | 6.88 | 7.32 | 8.12 | 10.18 | 1.79 | 1.14 | 2.45 | 15.04 | 38.49 | 40.45 |
Total Current Liabilities & Provisions | 271.33 | 214.03 | 155.76 | 111 | 66.08 | 45.39 | 44.37 | 36.36 | 70.57 | 118.51 |
Net Current Assets | 649.38 | 699.19 | 433.66 | 260.11 | 177.98 | 226.62 | 188.14 | 180.25 | 133.47 | 250.15 |
Deferred Tax Assets | 2 | 1.87 | 0.89 | 0.43 | 0.84 | 0.61 | 0.61 | 0.58 | 1.52 | 1.52 |
Deferred Tax Liability | 11.41 | 10.51 | 9.9 | 8.92 | 11.64 | 7.64 | 6.62 | 5.92 | 1.83 | 2.02 |
Net Deferred Tax | -9.41 | -8.64 | -9.01 | -8.49 | -10.8 | -7.03 | -6.01 | -5.34 | -0.31 | -0.5 |
Other Assets | 31.01 | 17.5 | 4.16 | 4.16 | 4.47 | 1.29 | 0.82 | 0.59 | 1.25 | 0.83 |
Total Assets | 1,235.31 | 1,122.19 | 800.83 | 621.21 | 522.9 | 559.56 | 506.91 | 504.07 | 463.32 | 408.11 |
Contingent Liabilities | 0 | 1.45 | 1.45 | 115.1 | 140.38 | 71.35 | 11.05 | 0 | 9.71 | 0 |
Cash Flow (Figures in Rs. Crores)
Net Profit before Tax and Extr... | 423.53 |
Depreciation | 74.27 |
Interest (Net) | -22.58 |
P/L on Sales of Assets | -0.09 |
P/L on Sales of Invest | -0.05 |
Prov. and W/O (Net) | 5.16 |
P/L in Forex | 3.04 |
Total Adjustments (PBT and Ext... | 55.42 |
Operating Profit before Workin... | 478.95 |
Trade and 0ther Receivables | -37.17 |
Inventories | -112.67 |
Total Adjustments (OP before W... | -126.19 |
Cash Generated from/(used in) ... | 352.76 |
Direct Taxes Paid | -122.35 |
Total Adjustments(Cash Generat... | -122.35 |
Cash Flow before Extraordinary... | 230.41 |
Net Cash from Operating Activi... | 230.41 |
Purchased of Fixed Assets | -208.84 |
Sale of Fixed Assets | 0.85 |
Purchase of Investments | -37 |
Sale of Investments | 11.05 |
Interest Received | 30.87 |
Net Cash used in Investing Act... | -140.84 |
Of the Short Term Borrowings | -12.5 |
Of Financial Liabilities | -28.4 |
Dividend Paid | -22.66 |
Interest Paid | -5.17 |
Net Cash used in Financing Act... | -68.73 |
Net Profit before Tax and Extr... | 171.89 |
Depreciation | 29.13 |
Interest (Net) | -21.51 |
Dividend Received | 25.77 |
P/L on Sales of Assets | -0.03 |
P/L on Sales of Invest | -0.05 |
Prov. and W/O (Net) | 3.11 |
P/L in Forex | 3.04 |
Total Adjustments (PBT and Ext... | -16.4 |
Operating Profit before Workin... | 155.5 |
Trade and 0ther Receivables | -70.24 |
Inventories | -59.9 |
Total Adjustments (OP before W... | -82.68 |
Cash Generated from/(used in) ... | 72.82 |
Direct Taxes Paid | -38.76 |
Total Adjustments(Cash Generat... | -38.76 |
Cash Flow before Extraordinary... | 34.05 |
Net Cash from Operating Activi... | 34.05 |
Purchased of Fixed Assets | -155.67 |
Sale of Fixed Assets | 0.33 |
Purchase of Investments | -37 |
Sale of Investments | 11.05 |
Interest Received | 19.65 |
Net Cash used in Investing Act... | -114.22 |
Of Financial Liabilities | -3.56 |
Dividend Paid | -22.66 |
Net Cash used in Financing Act... | -26.22 |
Company Details
Registered Office |
|
Address | 11th Flr GRANDEUR Oshiwara, Veera Desai Extn Rd Andheri(W) |
City | Mumbai |
State | Maharashtra |
Pin Code | 400053 |
Tel. No. | 91-22-40012000 |
Fax. No. | 91-22-40012011 |
companysecretary@marksanspharma.com ; info@marksan | |
Internet | http://www.marksanspharma.com |
Registrars |
|
Address | 11th Flr GRANDEUR Oshiwara |
City | Mumbai |
State | Maharashtra |
Pin Code | 400053 |
Tel. No. | 91-22-40012000 |
Fax. No. | 91-22-40012011 |
companysecretary@marksanspharma.com ; info@marksan | |
Internet | http://www.marksanspharma.com |
Management |
|
Name | Designation |
Mark Saldanha | Chairman & Managing Director |
Harshavardhan Panigrahi | Company Sec. & Compli. Officer |
Seetharama Raju Buddharaju | Non-Exec. & Independent Dir. |
Sandra Saldanha | Whole-time Director |
Digant Mahesh Parikh | Non-Exec. & Independent Dir. |
Varddhman Vikramaditya Jain | Whole-time Director |
Abhinna Sundar Mohanty | Non-Exec. & Independent Dir. |
Sunny Sharma | Non Executive Director |
Shailaja Vardhan | Independent Director |